Current Research in Translational Medicine

Scope & Guideline

Pioneering Translational Science for Global Health Advancements

Introduction

Immerse yourself in the scholarly insights of Current Research in Translational Medicine with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2452-3186
PublisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
Support Open AccessNo
CountryFrance
TypeJournal
Convergefrom 2016 to 2024
AbbreviationCURR RES TRANSL MED / Curr. Res. Transl. Med.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE

Aims and Scopes

Current Research in Translational Medicine focuses on bridging the gap between laboratory research and clinical applications, with a strong emphasis on hematological malignancies and innovative therapies. The journal aims to publish high-quality research that contributes to the understanding and management of various medical conditions, particularly through translational approaches.
  1. Hematological Malignancies:
    The journal consistently publishes research related to hematological cancers, including acute myeloid leukemia, lymphoma, and multiple myeloma, focusing on novel treatments and therapeutic strategies.
  2. Translational Research:
    A core aim is to translate laboratory findings into clinical applications, emphasizing studies that bridge experimental and clinical medicine.
  3. Cell and Gene Therapy:
    Research on cell-based therapies, particularly CAR-T cell therapy and stem cell transplantation, is a significant focus, highlighting advancements in treatment methodologies.
  4. Immunotherapy:
    The journal covers emerging immunotherapeutic strategies, investigating their efficacy and safety in treating various malignancies.
  5. Biomarkers and Diagnostics:
    There is a strong emphasis on identifying biomarkers for disease prognosis and treatment response, contributing to personalized medicine.
  6. Regenerative Medicine:
    Research involving stem cells and regenerative therapies is prevalent, showcasing innovative approaches to repair and regenerate damaged tissues.
  7. Clinical Guidelines and Best Practices:
    The journal also addresses clinical practices through guidelines and recommendations for managing hematological disorders.
Current Research in Translational Medicine is witnessing a surge in certain emerging themes that reflect the evolving landscape of medical research. This section outlines these trending areas, which are gaining prominence in recent publications.
  1. CAR-T Cell and Novel Immunotherapies:
    The increasing focus on CAR-T cell therapy and other immunotherapeutic approaches highlights the journal's commitment to cutting-edge treatments and their applications in hematological malignancies.
  2. Next-Generation Sequencing and Genomics:
    There is a growing trend towards incorporating genomic technologies such as next-generation sequencing, which aids in understanding the genetic underpinnings of diseases and personalizing treatment.
  3. Biomarker Discovery and Application:
    Research aimed at discovering and validating biomarkers for various hematological conditions is on the rise, enhancing the capabilities of precision medicine.
  4. Artificial Intelligence and Data Analytics:
    The integration of AI and data analytics in predicting treatment outcomes and patient responses is emerging as a significant trend, reflecting the journal's adaptation to technological advancements.
  5. Regenerative and Stem Cell Therapies:
    An increasing number of studies are exploring the potential of regenerative medicine and stem cell therapies, indicating a shift towards innovative approaches in treatment.
  6. Clinical Guidelines and Evidence-Based Practices:
    There is a noticeable trend towards publishing clinical guidelines and recommendations, aiming to standardize practices and improve patient care in hematological oncology.

Declining or Waning

While Current Research in Translational Medicine maintains a robust focus on hematological disorders and innovative therapies, certain themes have shown signs of decline in recent publications. This section highlights these waning areas.
  1. Solid Tumor Research:
    Research specifically focused on solid tumors has decreased, indicating a shift towards hematological malignancies and therapies related to blood cancers.
  2. Traditional Pharmacotherapy:
    There appears to be a reduction in studies centered on conventional pharmacological treatments, as innovative therapies like immunotherapy and gene therapy become more prominent.
  3. Infectious Disease Research:
    While COVID-19 research was significant during the pandemic, the volume of papers addressing infectious diseases outside the context of hematological malignancies has lessened.
  4. Basic Science Studies:
    There is a noticeable decline in purely basic science research that does not directly translate to clinical applications, as the journal increasingly emphasizes translational studies.

Similar Journals

Blood Science

Pioneering Research for Better Blood Health
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

Revista Romana de Medicina de Laborator

Exploring Breakthroughs in Biochemistry and Beyond
Publisher: SCIENDOISSN: 1841-6624Frequency: 4 issues/year

Revista Romana de Medicina de Laborator is a prominent open-access journal published by SCIENDO, dedicated to the field of medical laboratory technology and biochemistry. Since its inception, this journal has been a vital platform for disseminating research findings and advancements in laboratory medicine. With an ISSN of 1841-6624 and E-ISSN 2284-5623, it has served the academic community since 2008 and has embraced an open-access model since 2013, ensuring that valuable research is accessible to all. While it features niche rankings in Scopus for areas such as Medical Laboratory Technology and Clinical Biochemistry, it consistently strives to engage researchers, professionals, and students. Its rich collection of articles highlights innovative techniques and methodologies, supporting the ongoing development of laboratory practices. Although its coverage in Scopus has been discontinued, the journal continues to publish high-quality studies that contribute significantly to the field, fostering knowledge exchange essential for advancing medical science.

Egyptian Journal of Haematology

Exploring Breakthroughs in Blood Health and Disease
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

LEUKEMIA RESEARCH

Advancing knowledge in leukemia and hematological disorders.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0145-2126Frequency: 12 issues/year

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

HEMATOLOGICAL ONCOLOGY

Fostering Excellence in Cancer Research and Treatment
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

Journal of Stem Cells & Regenerative Medicine

Innovating Tomorrow's Regenerative Solutions
Publisher: JOURNAL STEM CELLS & REGENERATIVE MEDICINEISSN: 0973-7154Frequency: 2 issues/year

The Journal of Stem Cells & Regenerative Medicine is a leading publication dedicated to the advancing field of stem cell research and regenerative medicine. Established in India and published by JOURNAL STEM CELLS & REGENERATIVE MEDICINE, this Open Access journal has been available since 2007, providing researchers and practitioners with free and unrestricted access to high-quality articles. With an ISSN of 0973-7154, the journal is indexed in Scopus, featuring a wide array of topics and insights into biochemistry, biotechnology, cell biology, and molecular biology, as denoted by its relevant quartile rankings. This journal is committed to bridging the gap between laboratory research and clinical applications, making significant contributions to the scientific community. The convergence of innovative studies from 2010 to 2024 positions it as an invaluable resource for those looking to stay at the forefront of stem cell and regenerative medicine research.

npj Regenerative Medicine

Shaping the Future of Therapeutic Advancements.
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Regenerative Medicine, published by NATURE PORTFOLIO, is at the forefront of research and innovation in the field of regenerative medicine, fostering a deep understanding of cellular and molecular processes that can be leveraged for therapeutic advancements. Launched as an Open Access journal since 2016, it ensures wide dissemination of knowledge, allowing researchers, professionals, and students to access high-quality articles without barriers. With an impressive impact, it holds Q1 ratings across multiple categories including Biomedical Engineering, Cell Biology, Developmental Biology, and Medicine (miscellaneous) as of 2023, indicating its critical role in shaping contemporary scientific discourse. The journal ranks notably within the top 10% in multiple Scopus categories, indicating its commitment to publishing pioneering research that addresses pressing challenges in regenerative therapies. Addressing the dynamic convergence of disciplines, npj Regenerative Medicine is poised to not only impact academic thought but also translate into clinical applications, making it a pivotal resource for those invested in the future of medicine.

Hematology Transfusion and Cell Therapy

Pioneering insights in hematology and transfusion care.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Journal of Hematology & Oncology

Catalyzing Breakthroughs in Blood Health and Cancer Care
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

Hematologie

Pioneering Discoveries in Hematology
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.